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Purpose: It is widely believed that chronic renal insufficiency (CRI) greatly increases the risk associated with endovascular
abdominal aortic aneurysm repair (EVAR) and is a relative contraindication to the procedure and to the use of
intra-arterial contrast agents (IACA). We reviewed a 5-year EVAR experience to determine whether the procedure and
use of IACA have an important deleterious effect on renal function in patients with and without pre-existing CRI.
Methods: Endovascular aneurysm repair (EVAR) was performed in 200 patients with a variety of endografts, with
intra-arterial contrast agents. The patients were retrospectively assigned to three groups on the basis of preoperative
serum creatinine concentration (Cr): group 1 (n  108), Cr less than 1.5 mg/dL (normal range); group 2 (n  65), Cr
1.5 to 2.0 mg/dL; group 3 (n  27), Cr 2.1 to 3.5 mg/dL. No patients had undergone hemodialysis. In groups 2 and
3, patients received hydration perioperatively, and received mannitol intraoperatively; no nephrotoxic drugs were
administered during the procedure, other than nonionic contrast agent (Omnipaque 350).
Results: The incidence of postoperative complications between the three study groups was not statistically different. In
group 1 a transient increase in serum Cr (>30% over baseline and >1.4 mg/dL) was noted in three patients (2.7%), two
of whom (1.9%) required temporary hemodialysis and one (0.9%) who died of renal failure. In group 2 a transient increase
in serum Cr was noted in two patients (3.1%); both patients (3.1%) required temporary hemodialysis, and one patient
(1.5%) died of renal failure. In group 3 a transient increase in serum Cr was noted in two patients (7.4%); one patient
(3.7%) required temporary hemodialysis, and one patient (3.7%) died of renal failure. Perioperative hypotension
significantly increased the risk for elevated serum Cr and death (P < .05), and larger contrast volume was associated with
an increase in serum Cr (P < .05) during the postoperative period.
Conclusions: EVAR with intra-arterial contrast agents can be accomplished in patients with chronic renal insufficiency
who do not require dialysis, with limited and acceptable morbidity and mortality, similar to that observed with open
aneurysm repair. Contrary to other reports in which perioperative precautions were not used, our study shows that with
EVAR the risk for worsening renal failure, dialysis, and death is only slightly, and not significantly, greater in patients
with preoperative chronic renal insufficiency compared with patients with normal renal function. Perioperative hypoten-
sion and increased contrast volume are significant risk factors for postoperative increase in serum Cr and death. With
appropriate precautions such as averting perioperative hypotension and limiting the volume of nonionic contrast agents,
elevated Cr need not be a contraindication to EVAR with intra-arterial contrast agents. (J Vasc Surg 2004;39:118-23.)
Over the past decade endovascular aneurysm repair
(EVAR) with intra-arterial contrast agents has become an
established method for aortoiliac aneurysm repair. It re-
quires intra-arterial administration of radiographic contrast
agents, which can cause impaired renal function leading to
end-stage renal disease. Chronic renal insufficiency is a
relative contraindication to use of intra-arterial contrast
agents and is thought to further increase the risks of EVAR.
After open aortoiliac aneurysm repair, renal insufficiency is
a well-recognized complication; however, its incidence af-
ter EVAR remains poorly documented. We reviewed a
5-year experience with EVAR to determine whether the
procedure, when performed with intra-arterial contrast
agents, has important deleterious effects on renal function
in patients with and without preexisting chronic renal in-
sufficiency.
METHODS
From January 1996 to December 2000, all patients
with an abdominal aortic aneurysm (AAA) larger than 5.4
cm in diameter, with and without iliac involvement, were
eligible for EVAR and standard open surgical repair. Pa-
tients at high risk, with severe cardiopulmonary disease,
hostile abdomen, or other major comorbid condition, were
offered treatment with a variety of commercial endografts,
including Vanguard (Boston Scientific, Natick, Mass), Tal-
ent (Medtronic, Sunrise, Fla), Ancure (Guidant-EVT,
Menlo Park, Calif), AneuRx (Medtronic), Excluder (W. L.
Gore & Associates, Flagstaff, Ariz), and Zenith (Cook,
Bloomington, Ind). Because of unsuitable anatomy or un-
availability of commercial stent grafts, patients considered
at high risk underwent EVAR with surgeon-made en-
dografts (MEGS, Montefiore Endovascular Grafting Sys-
tem; Montefiore Medical Center, New York, NY). These
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techniques were also offered to some patients at better risk
when protocols became available.
Our technique for EVAR has been described else-
where.1 In brief, the endografts were fixed proximally just
below the renal arteries, and distal fixation sites were either
the common iliac artery, external iliac artery, or femoral
artery. When an aortoiliac aneurysm extended to the iliac
bifurcation, Gianturco coils (Cook) were used to exclude
flow to the hypogastric arteries, either preoperatively or
intraoperatively. Routine precautions in patients with
chronic renal insufficiency included preoperative intrave-
nous hydration with 2 L of normal saline solution, discon-
tinuation of all nephrotoxic drugs, intraoperative adminis-
tration of mannitol (0.5 g/kg intravenously), and use of
nonionic, low osmolar intra-arterial contrast agent (Om-
nipaque 350). Furthermore, to limit the cumulative neph-
rotoxic effects of intravascular contrast agents, preoperative
and perioperative imaging, including computed tomogra-
phy (CT) and arteriography, and EVAR were routinely
staged at least 2 weeks apart. Although low osmolar intra-
arterial contrast agent (Omnipaque 350) was also routinely
used in all patients, administration of mannitol and use of
preoperative intravenous hydration was not standard pro-
tocol in patients with normal preoperative serum creatinine
concentration (Cr; group 1).
Charts, operative reports, and laboratory data were
reviewed. In the initial postoperative period serum Cr was
measured on postoperative days 1 and 2. Patients with
worsening renal function, illustrated by an increase in se-
rum Cr, were observed with daily serum Cr measurement
until acute tubular necrosis resolved or improved. In these
patients, serum Cr was also measured at the postoperative
office visit at 1 to 2 weeks. Creatinine clearance indicated
measure of glomerular filtration rate (GFR), and was cal-
culated with the Cockroft formula: GFR (140 Age)
Weight (kg)/(0.81 Serum Cr [mol/L]). Patients were
retrospectively assigned to three groups on the basis of
preoperative serum Cr: group 1 (n 108), Cr less than 1.5
mg/dL (normal range); group II (n  65), Cr 1.5 to 2.0
mg/dL; group 3 (n  27), Cr 2.1 to 3.5 mg/dL. No
patients had a history of hemodialysis (Table I). Exclusion
criteria included chronic renal insufficiency requiring he-
modialysis, and symptomatic high-grade renal artery steno-
sis requiring renal angioplasty and stenting. Analysis was
performed with the Fisher exact test, and univariate or
multivariate analysis with binary logistic regression. All tests
were two-tailed and tested at the   0.05 level.
RESULTS
Over the 5-year period, 200 patients underwent EVAR
with intra-arterial contrast agents. Of these, 108 patients
had normal renal function (group 1), and 92 patients had
pre-existing chronic renal insufficiency with baseline Cr 1.5
to 2.0 mg/dL (group 2, n  65) or 2.1 to 3.5 mg/dL
(group 3, n  27). Average patient age was 72.2 years.
Comorbid conditions included coronary artery disease
(group 1, 51%; group 2, 49%; group 3, 59%), hypertension
(group 1, 39%; group 2, 46%; group 3, 52%), and diabetes
mellitus (group 1, 25%; group 2, 35%; group 3, 48%; Table
I). Mean diameter of AAAs was 6.2 cm, and of iliac aneu-
rysms was 4.2 cm. Intraoperative hemodynamic instability,
defined as systolic blood pressure less than 80 mm Hg or
greater than 40% decrease from normal for more than 10
minutes, and amount of nonionic low osmolar contrast
agent used during EVAR are given in Table II. At postop-
erative follow-up at 1 to 2 weeks, serum Cr was routinely
checked, and no patients with normal serum Cr at hospital
discharge exhibited a delayed rise in serum Cr value.
Rate of postoperative complications between the three
study groups was not significantly different. Perioperative
serum Cr for individual patients and mean Cr clearance for
each group is depicted in Figs 1 and 2. In group 1 a
transient increase in serum Cr (30% over baseline and
Table II. Intraoperative risk factors in patients
undergoing EVAR
Preoperative Cr (mg/dL)
Group 1 Group 2 Group 3
1.5 1.5-2.0 2.1-3.5
Number of patients 108 65 27
Intra-arterial contrast agent (mL) 210 160 130
Hemodynamic instability 3 1 1
EVAR, Endovascular abdominal aortic aneurysm repair; Cr, creatinine
concentration.
Table I. Demographic data and preoperative risk factors in patients undergoing EVAR
Preoperative Cr
(mg/dL)
Group 1 Group 2 Group 3
1.5 1.5-2.0 2.1-3.5
n % n % n %
Number of patients 108 65 27
Male 91 84 54 83 21 78
Female 17 16 11 17 6 22
Diabetes mellitus 27 25 23 35 13 48
Hypertension 42 39 30 46 14 52
Coronary artery disease 55 51 32 49 16 59
EVAR, Endovascular abdominal aortic aneurysm repair; Cr, creatinine concentration.
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1.4 mg/dL) was noted in three patients (2.7%); two
patients (1.9%) required temporary hemodialysis, and one
patient (0.9%) died of renal failure. In group 2 a transient
increase in serum Cr was noted in two patients (3.1%); both
patients (3.1%) required temporary hemodialysis, and one
patient (1.5%) died of renal failure. In group 3 a transient
increase in serum Cr was noted in two patients (7.4%); one
patient (3.7%) required temporary hemodialysis, and one
patient (3.7%) died of renal failure (Table III). Overall
30-day mortality secondary to causes other than renal fail-
ure was 3.7% in group 1, 4.5% in group 2, and 3.7% in
group 3. Univariate analysis failed to indicate coronary
artery disease, hypertension, and diabetes mellitus as signif-
icant risk factors for worsening renal insufficiency or death.
Univariate and multivariate analysis indicated that presence
of perioperative hypotension and use of larger volumes of
contrast agent significantly increased risk for increased
postoperative serum Cr (P  .001). Furthermore, chronic
renal insufficiency increased the risk for dialysis (P  .05),
and perioperative hypotension increased the risk for death
(P  .03; Table IV).
DISCUSSION
Chronic renal insufficiency increases the incidence of
contrast-induced nephrotoxicity. High osmolar contrast
agents, dehydration, nephrotoxic drugs, and diabetes mel-
litus further increase the risk for worsening renal failure.2-4
Renal insufficiency is a well-recognized complication after
open AAA repair; its incidence after EVAR remains poorly
documented. The incidence of worsening renal function in
patients undergoing open surgical AAA repair with normal
preoperative renal function is 5.4%, and increases two- to
threefold in patients with preexisting chronic renal insuffi-
ciency.5,6 Mortality with associated renal failure in patients
undergoing EVAR with and without preexisting chronic
renal insufficiency has been reported at 47% and 3%, respec-
tively.7 Contrary to that report, our findings demonstrate
that with perioperative precautions, including adequate
intravenous hydration, use of low osmolar contrast agents,
avoidance of nephrotoxic drugs, and use of mannitol to
promote diuresis, risk for worsening renal failure is low and
not significantly increased in patients with preexisting
chronic renal insufficiency compared with patients with
normal renal function.
EVAR requires administration of intra-arterial contrast
agents that have potential to produce hemodynamic
changes in the kidney within 24 to 48 hours. These contrast
agents induce renal vasoconstriction and interfere with
water and sodium absorption by the renal tubules, leading
to increased renal vascular resistance and decreased GFR,
respectively.8 Subsequent renal failure is manifested as an
increase in serum Cr and a decrease in Cr clearance.
Chronic renal insufficiency prolongs the elimination half-
life of the contrast agents, leading to increased renal expo-
sure and nephrotoxicity. Patients with chronic renal insuf-
ficiency, particularly in association with diabetic
nephropathy and dehydration, are increasingly susceptible
to the deleterious effects of intra-arterial contrast agents.
Low osmolar nonionic contrast agents result in diminished
reduction in renal blood flow and are associated with
reduced adverse effects, compared with high osmolar ionic
contrast agents.4,9 The association between contrast vol-
ume and nephrotoxicity remains controversial; some inves-
tigators have reported a significant correlation, whereas
others have found no relationship.3,4 During our earlier
Fig 2. Mean creatinine clearance in perioperative period. Group 1
(triangles), 1.5 mg/dL; group 2 (squares), 1.5-2.0 mg/dL;
group 3 (circles), 2.1-3.5 mg/dL.
Fig 1. Perioperative serum creatinine concentration in individual
patients.
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experience with EVAR, much larger volumes of contrast
agents were used. However, over the past 2 years we have
developed a number of methods to decrease contrast load
in all patients, including use of an automated volume
controllable power injector to deliver intra-arterial contrast
(Acist, Eden Prairie, Minn); performing arteriography only
with minimal volume of contrast agent after the device is in
place, near the level of the renal arteries; and not perform-
ing contrast-enhanced imaging studies within 2 weeks of
the procedure.
We have adopted several strategies to reduce the
amount of contrast agent used during EVAR. Bony lumbar
vertebral landmarks are used to approximate the level of the
renal arteries (usually L1-2) and position the main body of
the modular stent graft. Automated power injectors are
used to infuse low volumes of contrast agents (5-10 mL)
delivered at high flow rate (5 mL of contrast agent at 25-30
mL/s) to mark the positions of the renal arteries. Aortoiliac
aneurysm length and diameter measurements can be based
on preoperative CT scans and arteriograms. When preop-
erative imaging for EVAR evaluation includes only CT or
magnetic resonance angiography, which is often the case in
patients with preexisting chronic renal insufficiency, ade-
quate intraoperative arteriograms can be obtained with as
little as 15 mL of contrast agent and optimizing digital
subtraction techniques. After deployment of the main body
and cannulation of the contralateral limb, again 5 to 10 mL
of contrast agent can be used to mark the position of the
contralateral hypogastric artery. Finally, a completion arte-
riogram to evaluate the adequacy of proximal and distal
fixation and the presence of endoleaks generally requires 20
to 25 mL of contrast agent. In our experience, use of less
than 20 mL of contrast agent to evaluate endoleaks, partic-
ularly type II (retrograde flow through lumbar and inferior
mesenteric arteries) and type IV (prograde flow through
graft porosity) generates suboptimal images, and repeat
arteriography is required. If adequate intraoperative digital
subtraction imaging is available, non-nephrotoxic gadolin-
ium-based contrast agents can generate adequate images. If
gadolinium fails to produce adequate opacification, it can
be used to dilute low osmolar nonionic contrast agents
(50:50 mixture) and further enhance digital subtraction
images. Although gadolinium-based contrast agents were
not used in the cohort of patients in this study, we have
found it useful in limiting the amount of nephrotoxic
contrast agent during EVAR.
In a prospective, placebo-controlled, randomized trial
of patients with chronic renal insufficiency at risk for con-
trast-induced renal damage, acetylcysteine (Mucomyst)
was beneficial in preventing renal damage.10 Acetylcysteine
is an antioxidant that at doses of 600 mg orally twice daily
on the day before and the day of administering intravascular
contrast agent prevented worsening of renal function in
patients with preexisting chronic renal insufficiency.
Table IV. Effects of preexisting comorbid conditions on worsening renal function and death
Increased serum
creatinine concentration Dialysis 30-day mortality
P OR P OR P OR
Coronary artery disease 0.5 1.5 0.4 2.1 0.6 0.8
Hypertension 0.6 0.8 0.5 1.9 0.6 1.4
Diabetes mellitus 0.6 1.4 0.4 1.9 0.5 0.5
Chronic renal insufficiency 0.4 1.6 0.02 5.0 0.2 2.1
Perioperative hypotension 0.001 9.1 0.1 2.1 0.03 4.8
Contrast agent volume (50 mL increments) 0.001 1.6 0.8 1.0 0.4 0.9
OR, Odds ratio.
*Univariate analysis, binary logistic regression.
Table III. Postoperative renal complication and mortality after EVAR
Preoperative Cr (mg/dL)
Group 1 Group 2 Group 3
P*
1.5 1.5-2.0 2.1-3.5
n % n % n %
Number of patients 108 65 27
Cr increase† 3 2.7 2 3.1 2 7.4 NS
Temporary dialysis 2 1.9 2 3.1 1 3.7 NS
Death and renal failure 1 0.9 1 1.5 1 3.7 NS
Death without renal failure 4 3.7 3 4.5 1 3.7 NS
EVAR, Endovascular abdominal aortic aneurysm repair; Cr, creatinine concentration.
*Between-group difference not significant. In multivariate analysis comparing the three groups; power is 12%, type II error is 0.88.
†Transient increase 30% over baseline, and 1.4 mg/dL.
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Fenoldopam, a derivative of dopamine, also is effective in
preventing contrast media–induced nephrotoxicity.11 Over
several months we routinely used acetylcysteine in patients
with preexisting chronic renal insufficiency undergoing
EVAR. However, during the study, neither acetylcysteine
nor Fenoldopam was used.
To minimize the adverse effects of chronic renal insuf-
ficiency in our patients, we routinely staged preoperative
and perioperative CT, arteriography, and EVAR; discon-
tinued all possible nephrotoxic drugs; hydrated preopera-
tively with normal saline solution; infused intravenous
mannitol (0.5 g/kg) intraoperatively; and used limited
volumes of a low osmolar contrast agent (Omnipaque
350).
Patients with extensive aortoiliac aneurysms extending
to the iliac bifurcation or involving the internal iliac arteries
underwent flow interruption of unilateral or bilateral inter-
nal iliac arteries via coil embolization. Internal iliac artery
coil embolization in patients with preexisting chronic renal
insufficiency was always staged 1 to 2 weeks before
EVAR.12 Our results indicate that differences in the inci-
dence of postoperative increase in serum Cr, decrease in Cr
clearance, need for temporary dialysis, and death due to
renal failure were surprisingly not statistically significant
between patients with and without pre-existing chronic
renal insufficiency. This makes the argument for use of
carbon dioxide–based and gadolinium-based contrast
agents for arteriography and intravascular ultrasound to
facilitate EVAR.13,14 Although their use is feasible in se-
lected patients, these agents have limitations, and further
investigation is needed to assess short-term and long-term
results.
Overall, mean Cr clearance remained unchanged. As a
result of adequate preoperative and intraoperative hydra-
tion, Cr clearance initially improved during the first post-
operative day, and subsequently returned to baseline over
the next 2 to 3 days, implicating preservation of renal
function in patients with and without preexisting chronic
renal insufficiency (Fig 2). A transient increase in serum Cr
developed in three patients (2.7%) in group 1, two patients
(3.1%) in group 2, and two patients (7.4%) in group 3. All
of these patients received conservative supportive treat-
ment, and none required dialysis. Two patients (1.9%) in
group 1, two patients (3.1%) in group 2, and one patient
(3.7%) in group 3 required temporary dialysis. There were
no isolated identifiable differences in patients with transient
Cr increase compared with those requiring temporary dial-
ysis. None of these patients had suprarenal bare stent
fixation or inadvertent renal artery stent-graft coverage,
developed remarkable intraoperative hemodynamic insta-
bility, or received excessive intra-arterial contrast load.
In each of the three groups one death occurred second-
ary to renal failure as part of multisystem organ failure
(Table III). In all three patients the intraoperative course
was remarkable for either use of excessive amounts of
intra-arterial contrast agent, longer operative time, hemo-
dynamic instability, or coverage of the renal artery orifices
with bare stents or endografts. Unrecognized microembo-
lization secondary to catheter and wire manipulation dur-
ing EVAR also could have contributed to renal and multi-
system organ failure in these patients. Transrenal fixation of
the uncovered portion of the proximal stent grafts and
iatrogenic injury to the renal arteries, such as dissection or
stent graft coverage, are other possible causes of renal
insufficiency.15,16 Preexisting comorbid conditions, in-
cluding coronary artery disease, hypertension, and diabetes
mellitus, did not have an adverse effect on worsening renal
function or death. The presence of perioperative hypoten-
sion was associated with increased serum Cr and death (P
.05), and use of larger contrast volume was associated with
increased postoperative serum Cr (P .001). Patients with
perioperative hypotension were at ninefold increased risk
for worsening renal function (odds ratio, 9) and fivefold
increased risk for death (odds ratio, 5).
Our findings of limited morbidity and mortality from
use of intra-arterial contrast during EVAR are supported by
several other reports documenting a low incidence of renal
insufficiency after EVAR.17,18 Chuter et al19 reported their
experience in 116 patients at high risk undergoing EVAR.
Twenty-six of their patients with preexisting chronic renal
insufficiency received mean intra-arterial contrast volume
of 155 mL during EVAR, and a transient increase in serum
Cr developed postoperatively in only one patient.
In patients with chronic renal insufficiency, EVAR with
intra-arterial radiographic contrast agents is believed to
impair renal function, and chronic renal insufficiency is
considered a relative contraindication to the procedure.
Results of our investigation indicate that risk for worsening
renal insufficiency, dialysis, and death is only slightly and
not significantly greater in patients with chronic renal in-
sufficiency compared with patients with normal renal func-
tion. With appropriate precautions of avoiding periopera-
tive hypotension and limiting the volume of nonionic
contrast agents, chronic renal insufficiency need not be a
contraindication for EVAR with intra-arterial contrast
agents.
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